Silo Pharma Reports Results in Sterilization And Dissolution Testing Of SP-26 Ketamine Implant, Showing Stability And Consistent 7-Day Drug Release
Portfolio Pulse from Benzinga Newsdesk
Silo Pharma has reported positive results in the sterilization and dissolution testing of its SP-26 ketamine implant. The tests showed stability and a consistent 7-day drug release, which is a promising development for the company.
October 31, 2024 | 12:38 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Silo Pharma's SP-26 ketamine implant has shown stability and consistent 7-day drug release in recent tests, indicating a positive development for the company's product pipeline.
The successful testing of the SP-26 ketamine implant suggests potential for future product development and commercialization, which could positively impact Silo Pharma's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100